Akèy › Kansè tete negatif triple › New Mexico › Albuquerque
Etid klinik pou Kansè tete negatif triple nan Albuquerque, NM
3 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote Albuquerque (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Ap rekriteFaz 3
- New Mexico Oncology Hematology Consultants Ltd. ( Site 0019), Albuquerque
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Ap rekriteFaz 3
- New Mexico Oncology Hematology Consultants Ltd. ( Site 0090), Albuquerque
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Ap rekriteFaz 3
- University of New Mexico, Albuquerque
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Arlington, VA20 etid
- Atlanta, GA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
Lòt etid nan Albuquerque
- Kansè Poumon ki pa ti selil18 etid
- Kansè nan tete17 etid
- Kansè ovè15 etid
- Kansè (tout kalite)14 etid
- Kansè poumon14 etid
- Kansè Metastatik12 etid
- Kansè Endomèt12 etid
- Dyabèt Tip 211 etid
- Maladi kadyovaskilè10 etid
- Melanom9 etid
- Leksemi mieloïd egi9 etid
- Kansè pwostat9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.